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Our understanding of the benefits and risks of aspirin non steroidal anti-
inflammatory drugs (NSAIDs), cyclooxygenase-2 (COX-2) selective NSAIDs and
gastro-protective agents (GPAs) continues to expand.
Aim
To assess the perceptions and practices of US primary care physicians (PCPs)
regarding the use of aspirin, NSAIDs, COX-2 selective NSAIDs and GPA.
Methods
A 34-question survey was administered to 1000 US PCPs via the internet.
Questions addressed issues involving aspirin, NSAIDs, COX-2 selective NSAIDs,
and GPAs. Around 491 of 1000 PCPs had participated in a similar survey con-
ducted in 2003.
Results
Eighty-five per cent of PCPs reported that >25% of their patients were taking
aspirin for preventive reasons. Nineteen per cent performed a risk calculation
when deciding whether to start aspirin for cardioprotection. Fifty-four per cent
recommended a proton pump inhibitor (PPI) for a patient with a recently
healed ulcer who required ongoing aspirin. Thirty-one per cent reported pre-
scribing NSAIDs more often and 52% were more likely to recommend a GPA
with an NSAID than in 2003. Although PCPs were less likely to recommend a
COX-2 selective NSAID compared to 2003, only 41% felt that rofecoxib
increased cardiovascular risk. One-third felt that celecoxib and traditional
NSAIDs were associated with increased cardiac risk.
Conclusion
This survey identified several areas of ongoing confusion regarding aspirin,
NSAIDs, COX-2 selective NSAIDs and GPAs, which should help direct future
educational efforts regarding the benefits, risks and appropriate use of these
agents.
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INTRODUCTION
Nonsteroidal anti-inflammatory drugs (NSAIDs)
including aspirin are the most widely used drugs in
the world. Prescribed by physicians and purchased by
consumers over the counter, it is estimated that mil-
lions of people take these drugs on a daily basis.1 In
addition to NSAID use for pain control, aspirin is com-
monly used for cardioprotection,2, 3 as well as chemo-
prophylaxis for a number of malignancies.4–6 Serious
adverse events, ranging from dyspepsia to upper and
lower gastrointestinal (GI) bleeding, perforation and
obstruction, have been attributed to NSAID or aspirin
use.7–12 Cyclooxygenase-2 (COX-2) specific inhibitors
(COX-2 selective NSAIDs) provide an alternative to
nonselective NSAIDs that confer a reduced risk for
serious GI toxicity.13–16 However, the withdrawal of
two COX-2 selective NSAIDs from the US market and
failure to approve two others primarily for reasons of
cardiovascular (CV) safety,17–20 have negatively
impacted the prescription of COX-2 selective NSAIDs
and have drawn attention to the use of gastroprotec-
tion concomitant with NSAID use.21
Primary care physicians (PCPs) are responsible for
the largest proportion of NSAID prescriptions. How-
ever, incorporation of new information by healthcare
providers in this area, which is undergoing rapid data
accrual, can be slow and is subject to influence from
promotional efforts of the pharmaceutical industry,
which not only target prescribers, but aggressively
market directly to consumers. The recognition of
adverse CV events associated with COX-2 selective
NSAIDs has led to confusion regarding the use of
these medications in patients with increased GI and ⁄ or
CV risk. Uncertainty also remains regarding the appro-
priate use of low dose aspirin and NSAIDs.
There has been a rapid evolution of information
addressing the use of aspirin, NSAIDs, COX-2 selective
NSAIDs and gastroprotective agents (GPAs). As such,
it is important to identify those areas in which PCPs
need further education. In 2003, we surveyed 1000 US
PCPs to assess their perceptions and prescribing habits
as they pertain to these agents.22 That survey identi-
fied multiple areas of misinformation regarding the
risk-benefit of NSAIDs and aspirin as well as appropri-
ate utilization of gastroprotective strategies. For exam-
ple, a majority of PCPs felt that enteric coating
reduced the risk of adverse GI events. In addition, at
the time of our original survey, PCPs recommended a
COX-2 selective NSAID in a patient requiring an
NSAID over 40% of the time. There was confusion
about the interaction between aspirin and COX-2
selective NSAIDs and the use of gastroprotection in
patients at increased risk for GI adverse events who
required ongoing treatment with an NSAID or aspirin.
In light of changes in COX-2 selective NSAID avail-
ability in the US and new data on indications and the
safety of aspirin and NSAIDs, we conducted a follow-
up survey to assess current perceptions on the safety
and appropriate use of these drugs.
METHODS
A 34 question survey was independently developed by
a group of academic physicians and was administered
via the internet to US PCPs. PCPs who participated in
the 2003 survey22 were first targeted for enrolment in
this survey. Of the original 1000 participants, 491
PCPs enrolled in the 2006 survey. An additional 509
PCPs were recruited to achieve a final sample of 1000.
Roughly half of the questions were present on both
surveys.
Study population
To be eligible to participate in the study, participants
must have been a general practitioner, family practi-
tioner or internist in the US for at least two but no
more than 35 years. Physicians who spent more than
50% of their time in a teaching capacity were not eli-
gible for participation. The PCPs were accessed via a
panel provided by a professional Internet survey
research organization (Ziment, New York, NY, USA). A
fee of $25 was offered for completing the survey.
Funding for the services provided by the survey
research organization and participant honoraria were
provided by TAP Pharmaceuticals (Chicago, IL, USA),
who otherwise played no role in the design, interpreta-
tion or reporting of the results.
Survey administration
The specific survey questions are available in an Sup-
porting information. Participants had to complete each
question in sequence before proceeding to the next.
Once a question was completed and participants pro-
ceeded to the next question, they could not go back
and change an answer to a previous question. Partici-
pants were neither encouraged nor discouraged to use
reference materials when completing the survey.
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Questionnaire content
Aspirin related-issues. Questions investigated the
attitudes of PCPs regarding the use of aspirin as a pri-
mary and secondary cardioprotective agent. The PCPs
were queried on how often and at which dose they
recommend aspirin for cardioprotection. We asked
whether they felt that buffering or enteric coating of
aspirin reduced the risk of serious adverse GI out-
comes. We attempted to understand how they weighed
the risks and benefits of low dose aspirin when consid-
ering such therapy in an individual patient. We further
attempted to gauge how often they recommend a GPA
in patients taking low dose aspirin with or without a
traditional NSAID or COX-2 selective NSAID. We also
questioned them on the negative effects of some tradi-
tional NSAIDs on the antiplatelet effects of aspirin and
the impact of aspirin therapy on the GI safety benefits
of the COX-2 selective NSAIDs.
NSAIDs ⁄ COX-2 selective NSAIDs. We asked partici-
pants how often they recommended traditional NSAIDs
and COX-2 selective NSAIDs. In addition, we assessed
their use of GPAs including PPIs, histamine H2-recep-
tor antagonists (H2RAs) and misoprostol in patients
using these agents. We assessed whether they felt that
COX-2 selective NSAIDs as a class, specific COX-2
selective NSAIDs or traditional NSAIDs were associ-
ated with an increased risk of myocardial infarction.
We questioned about the potential interaction between
Helicobacter pylori infection and NSAIDs. We also
queried whether they felt that traditional NSAIDs were
associated with an increased risk of lower GI bleeding.
We assessed their perceptions regarding the compara-
tive risk of adverse GI outcomes in patients using
traditional NSAIDs vs. COX-2 selective NSAIDs.
Hypothetical patient scenarios. We presented partic-
ipants with a series of hypothetical patient scenarios
as outlined below:
A patient with a history of an ulcer-related upper GI
bleed who needs to be on antiplatelet therapy for sec-
ondary prevention of coronary artery disease (CAD).
A patient with an acute H. pylori-negative, NSAID-
associated gastric or duodenal ulcer.
A patient with a recently healed H. pylori-negative,
NSAID-associated ulcer, who requires an NSAID for
joint pain.
A person with a history of previous myocardial
infarction, but no previous or current GI problems,
who requires low-dose aspirin for cardioprotection and
an NSAID for arthritis-related pain.
A patient with a history of an ulcer-related upper GI
bleed who requires low dose aspirin for a history of
CAD and an NSAID for joint pain.
For each patient scenario, study participants were
presented with a series of clinical choices, which var-
ied based upon the specific case characteristics. The
specific case scenarios and potential answers can be
found in the Supporting information.
Statistical analysis
Descriptive statistics were employed to characterize the
survey responses. Comparisons between subgroups of
the study sample (gender-, age- and region-based
comparisons) were performed using the chi-squared test
(QUANTUM software; SPSS, Chicago, IL, USA). In situa-
tions where answers to a question created a continuous
variable, a Student’s t-test was utilized. A P-value of
<0.05 defined a statistically significant difference
between groups. When present, significant differences
in the data based on the gender, age and region of
residence are mentioned in the results section.
RESULTS
Survey participant demographics
A geographically diverse cohort of 1000 PCPs com-
pleted the on-line survey anonymously from 9 October
through 17 October, 2006. Demographics of PCPs were
similar in both surveys. Over 70% of participants were
between the ages of 35 and 54 years. Approximately
80% of the survey sample was male (Table 1). The
geographic distribution of our sample was diverse with
representation from 40 of the 50 states of the US. Sixty-
three per cent of PCPs reported that they were part of a
group practice, 28% were in solo private practice, and
9% were in partnerships. Thirty-four per cent of PCPs
practiced in communities of 100–500 K. Another 25%
practiced in metropolitan areas of >500 K. When asked
about payer mix, mean responses were as follows: 23%
HMO, 22% PPO, 10% POS, 26% Medicare, 8% Medicaid,
6% Other insurance and 5% No insurance.
We initially analysed answers from PCPs who par-
ticipated in the 2003 and current surveys separately
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from PCPs who only participated in the current survey.
However, because the answers between the two groups
of respondents were statistically similar, we have cho-
sen to present data for the pooled population of 1000
PCPs.
Questionnaire results
Aspirin related-issues. Eighty-five per cent of PCPs
felt that more than a quarter of their patients were
taking aspirin for prevention of CAD, stroke or other
indications such as prevention of colon cancer. Forty-
one per cent reported that more than half of their
patients were taking aspirin to prevent these condi-
tions. When asked how often they recommended aspi-
rin as primary preventive therapy for myocardial
infarction in persons over 60 years, 42% of PCPs
responded ‘always’ while 46% responded ‘most (>50%)
of the time’. This represented a change from 2003
when 66% PCPs stated that they ‘always’
recommended aspirin for the same type of patient. We
found that despite national guidelines to the contrary,
81% of PCPs do not perform a formal CV risk calcula-
tion prior to initiating aspirin therapy (Figure 1). We
noted some improvement in the understanding of the
risks associated with aspirin and strategies to reduce
that risk. In 2003, 69% recommended 81 mg of aspirin
as the preferred dosage; this increased to 82% in the
current survey. Fifteen per cent of PCPs continued to
recommend 325 mg of aspirin per day for cardio-
protection (Figure 2). Forty-six per cent of PCPs felt
that less than a quarter of their patients taking aspirin
were also taking a GPA. An additional 39% of PCPs
felt that between 25% and 49% of their patients taking
aspirin were taking a GPA. When the scenario was
changed to a patient taking both aspirin and an
NSAID, PCPs were more inclined to recommend gas-
troprotection. In fact, only 11.5% felt that less than a
quarter were taking gastroprotection while 55% felt
that more than half of their patients taking aspirin and
an NSAID were using a concomitant GPA. Sixty-one
per cent of PCPs surveyed believe that enteric coating
or buffering of aspirin reduces the risk of developing a
serious upper GI bleeding event compared to uncoated
and un-buffered aspirin. This result remained virtually
unchanged from 2003 when 59% of PCPs responded
in kind to the same question.
The current survey also addressed PCPs’ perceptions
regarding the potentially disruptive effect of specific
NSAIDs on the antiplatelet effect of aspirin. Eighty-
eight per cent were aware that some NSAIDs can
Yes, 19%
No, 81%
Figure 1. Response to the question: ‘When you are
deciding whether a patient needs aspirin for primary
prevention of coronary artery disease, do you perform a











Figure 2. Percentage of primary care physicians recom-
mending 81 mg vs. 325 mg ASA for cardioprotection.
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interfere with the antiplatelet effect of aspirin.
Among NSAIDs, PCPs were most concerned with ibu-
profen’s impact on the antiplatelet effect of aspirin.
Sixty-two per cent of respondents recognized this
important drug interaction. Despite evidence to the
contrary, 53% and 33% of PCPs felt that naproxen
and celecoxib also interfered with the antiplatelet
effect of aspirin. Eight per cent of respondents felt
that none of these agents interfered with aspirin and
15% responded that they did not know whether such
an interaction existed.
Regarding the potential impact of aspirin on the GI
safety benefits of the COX-2 selective NSAIDs, 65%
were aware that concurrent aspirin use reduced the GI
safety benefit of the COX-2 selective NSAIDs. This was
very similar to 2003 when 69% of PCPs were aware of
this drug interaction. Twenty-five per cent and 23% of
respondents in 2003 and in the current survey respec-
tively felt that concurrent aspirin therapy had no
effect on the GI safety benefit of the COX-2 selective
NSAIDs.
NSAIDs ⁄ COX-2 selective NSAIDs. Thirty-one per cent
of PCPs reported that they prescribe NSAIDs more
commonly now than in 2003, while 21% felt they pre-
scribed NSAIDs less commonly. Fifty-four per cent felt
that different traditional NSAIDs were associated with
differences in the likelihood of causing ulcers and
complications such as bleeding while 40% of respon-
dents that all traditional NSAIDs carried the same risk
of ulcers and bleeding. Fifty-two per cent reported that
they were more likely to recommend a GPA in patients
taking an NSAID. Ninety per cent of PCPs felt that
COX-2 selective NSAIDs offered improved GI safety
compared to traditional NSAIDs. In fact, PCPs most
commonly identified the potential GI safety benefits
offered by a COX-2 selective NSAID as the most
important reason they chose such an agent over a tra-
ditional NSAID. Fifty-nine per cent of PCPs reported
that they prescribed COX-2 selective NSAIDs less fre-
quently than in the 2003. In the 2003 survey, COX-2
selective NSAIDs accounted for 43% of all NSAID rec-
ommendations, whereas in the current survey, COX-2
selective NSAIDs accounted for only 25% of NSAID
recommendations (Figure 3).
Regarding COX-2 selective NSAIDs, NSAIDs and CV
safety, we found that 41% of PCPs felt that rofecoxib
was associated with a higher risk of MI compared with
not taking an NSAID, while 41% felt that there was no
increased risk of MI and 18% responded ‘don’t know’.
For celecoxib, 32% felt there was an increased risk of
MI compared to not taking an NSAID, while 53% felt
there was no increased risk of MI and 15% did not
know. Despite the fact that more than half of PCPs felt
there was no increased CV risk with celecoxib, 57%
reported that concerns regarding CV risk influence
their willingness to prescribe celecoxib. Thirty-five per
cent of PCPs felt that traditional NSAIDs were associ-
ated with increased CV risk, while 49% did not believe
this to be so and 16% did not know.
Seventy-one per cent of PCPs were aware that
H. pylori infection increases the risk of developing an
ulcer in patients taking an NSAID. This was similar to
2003 when 78% of PCPs reported being aware of the
additive ulcer risk of H. pylori infection and NSAID
use. Eighty per cent of PCPs rarely or never tested
their patients for H. pylori before starting an NSAID.
Seventy-eight per cent rarely or never tested their
patients already taking an NSAID for H. pylori. Both
values were virtually identical to responses offered to
the same questions in the 2003 survey.
Seventy-five per cent of PCPs felt that NSAIDs
increased the risk of lower GI bleeding. In 2003, 76%
were aware of this fact. Similar to 2003, roughly a
third of PCPs continued to feel that most patients with
an NSAID-associated ulcer bleed experienced anteced-
ent dyspeptic symptoms.
Hypothetical patient scenarios. A patient with a his-
tory of an ulcer-related upper GI bleed who needs to











Figure 3. Response to the question: ‘What percent of the
NSAID prescriptions that you prescribe are traditional
NSAIDs and what percent are COX-2 selective agents?’
P = 0.005, comparison of COX-2 selective nonsteroidal
anti-inflammatory drug between 2003 and 2006.
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Fifty-four per cent of PCPs chose to initiate gastro-
protective therapy with an over the counter (OTC)
(23%) or prescription (31%) PPI in this patient.
Twenty-six per cent chose to replace aspirin with clop-
idogrel, while another 12% chose to use enteric-coated
aspirin alone. Less than 5% chose co-therapy with an
H2RA or misoprostol.
A patient with an acute H. pylori-negative, NSAID-
associated gastric or duodenal ulcer.
For this patient, 95% of PCPs chose to use an OTC
PPI (12%) or prescription PPI q.d.s. (58%) or b.d. (24%).
A patient with a recently healed H. pylori-negative,
NSAID-associated ulcer, who requires an NSAID for
joint pain.
Eighty-eight per cent of PCPs chose gastroprotective
therapy with an OTC (22%) or prescription
(q.d.s. = 55%, b.d. = 11%) PPI. Eight per cent chose to
start this patient on an H2RA or misoprostol and 2%
recommended no gastroprotective therapy.
A person with a history of previous myocardial
infarction, but no previous or current GI problems,
who requires low dose aspirin for cardioprotection and
an NSAID for arthritis related pain.
Thirty-nine per cent of PCPs recommended no gas-
troprotective therapy for this patient. Twenty-seven
per cent chose to start this patient on an OTC or pre-
scription PPI while 8% chose co-therapy with an
H2RA. Interestingly, despite aspirin’s deleterious effects
on the GI safety benefits associated with a COX-2
selective NSAID, 26% of PCPs chose to replace the tra-
ditional NSAID with a COX-2 selective NSAID either
without (16%) or with (10%) a PPI.
A patient with a history of an ulcer-related upper GI
bleed who requires low dose aspirin for a history of
CAD and an NSAID for joint pain.
For this very high-risk patient, 44% of PCPs recom-
mended gastroprotective therapy with a PPI
(OTC = 15%, prescription = 28%). Forty-one per cent
chose to give a PPI and COX-2 selective NSAID in
place of the traditional NSAID. Six per cent and 4%
chose an H2RA or misoprotol for this patient, respec-
tively. Five per cent stated that they would treat with
aspirin and a traditional NSAID alone.
DISCUSSION
Our survey of US PCPs identified a number of areas of
improving knowledge regarding the use of aspirin,
traditional NSAIDs, COX-2 selective NSAIDs and
gastroprotective strategies. For example, we were
encouraged that a substantial proportion of PCPs are
recommending aspirin for cardioprotection. We were
also pleased to find that a significantly larger percent-
age of PCPs in the current survey were recommending
81 mg vs. 325 mg of aspirin for cardioprotection when
compared to 2003. A recent systematic review found
that higher doses of aspirin did not provide improved
cardioprotection compared to 70–85 mg ⁄ day, but were
associated with a higher incidence of GI adverse
events.23 Further, most PCPs correctly identified that
NSAIDs and H. pylori are independent risk factors for
peptic ulcer disease (PUD)24 and that NSAIDs could
cause lower GI as well as upper GI bleeding.25 We
were pleased that a majority of PCPs were aware of
the potential drug interactions between aspirin and
COX-2 selective NSAIDs. As the CLASS (Celecoxib
Long Term Arthritis Safety Study) trial originally
taught us and subsequent studies have confirmed, con-
comitant aspirin therapy reduces or eliminates the GI
safety benefits of COX-2 selective NSAIDs.15, 26 We
were also impressed that most PCPs were aware of the
potentially deleterious effects of ibuprofen on the anti-
platelet effect of aspirin.27, 28
At the same time, our survey clearly identified a
number of areas of confusion regarding the use of
these agents. While it is encouraging that the vast
majority of PCPs reported using the lower dose of
aspirin for cardioprotection, it is noteworthy that one
in seven PCPs continue to recommend 325 mg of aspi-
rin for this indication. It is also important to note that
more than 80% of PCPs surveyed continue to prescribe
aspirin for primary prophylaxis of CAD without any
formal risk calculation (Figure 2). While the benefits
of aspirin clearly outweigh the risks for secondary pre-
vention of CAD,3, 29 the determination of risk-benefit
for aspirin in the setting of primary prevention is more
complicated. National guidelines from the American
Heart Association have recommend aspirin for those
with a 10 years event risk of >10% for primary pre-
vention, while the US Preventive Services Task Force
is less conservative, recommending cardioprotection in
individuals with a 10 year event risk exceeding 6%.2, 3
Formal risk calculation helps clinicians balance the CV
benefits with the increased risk of significant GI bleed-
ing and haemorrhagic stroke that can complicate ther-
apy with low-dose aspirin.30–34 The lack of a formal
risk calculation before recommending aspirin makes it
likely that a substantial number of patients are being
exposed to the risks of aspirin in exchange for only a
low likelihood of benefit.
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Another area of considerable concern pertaining to
aspirin concerns the scenario in which a patient with a
history of previous ulcer bleeding required low dose
aspirin for cardioprotection. We were surprised that
only 54% of PCP respondents recommended gastro-
protection with a PPI for this patient at high risk for
an adverse GI outcome. On the other hand, almost
90% of PCPs recommended gastroprotection in a
patient with a recently healed ulcer who needed aspi-
rin for cardioprotection and an NSAID for joint pain.
Presumably, the disparity in results yielded by the two
scenarios reflects less concern when treating with only
low dose aspirin. It is important to realize that patients
with a history of ulcer bleeding have a remarkably
increased risk of ulcer recurrence and rebleeding in
the face of ongoing aspirin therapy without gastro-
protective therapy.35 In a randomized, controlled trial,
Lai et al.36 reported a 15% risk of recurrent ulcer
bleeding at 1 year in patients with a history of ulcer
bleeding who were replaced on aspirin and placebo vs.
<2% for patients randomized to aspirin and lansopraz-
ole 30 mg ⁄ day. Our results provide some of the first
such data from the US and confirm a recent study
from Manitoba, Canada which found that gastropro-
tective PPI therapy was prescribed in only 56% of
patients with a history of an upper GI complication
taking aspirin.37
Another point worthy of discussion has to do with
PCP perceptions of reducing the risk of GI adverse
events through the use of enteric-coated or buffered
aspirin. Similar to results obtained in our previous
2003 survey, we found that 66% of PCPs felt that
enteric-coated or buffered aspirin decreased the risk of
upper GI bleeding compared to plain aspirin. In fact,
for the scenario in which a patient with previous ulcer
bleeding required ongoing aspirin therapy for cardio-
protection, 12% of PCPs chose to replace plain aspirin
with enteric-coated aspirin rather than provide one of
the more evidence-based gastroprotective strategies.
The literature has shown that the risk of upper GI
bleeding associated with enteric-coated or buffered
aspirin is similar to that of plain aspirin.38–40
In the current survey, it was uncommon for PCPs to
recommend gastroprotection in patients without a pre-
vious history of ulcer bleeding. For example, in a
patient who required both aspirin and an NSAID, only
a quarter of PCPs recommended gastroprotection with
a PPI. This practice does not reflect recent studies,
which have shown that the addition of aspirin to
an NSAID significantly increases the risk of GI
toxicity.14, 30, 38, 41, 42
In contrast, for a patient with a previous history of
ulcer bleeding who needed both aspirin for cardiopro-
tection and an NSAID for joint pain, a higher propor-
tion of physicians recommended gastroprotection with
a PPI. In the corresponding case scenario, 85% of PCPs
said they would add a PPI to aspirin and an NSAID. It is
noteworthy that within this group, approximately half
of the PCPs stated that they would actually switch the
patient from a traditional NSAID to a COX-2 selective
NSAID in addition to recommending a PPI (Figure 4). It
was interesting that such a large proportion of PCPs still
recommended a COX-2 selective NSAID in a patient
who needed aspirin for cardioprotection, given that
COX-2 selective NSAIDs have been strongly associated
with dose related increased CV risk.18, 19, 43
We found that perceptions of COX-2 selective NSA-
IDs have changed since 2003. Fifty-nine per cent of
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aspirin for CAD and
NSAID joint pain
Figure 4. Percentage of pri-
mary care physicians recom-
mending proton pump
inhibitor for various scenarios.
ASA, aspirin; CAD, coronary
artery disease; UGIB, upper
gastrointestinal bleed.
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PCPs reported that they prescribe COX-2 selective NSA-
IDs less frequently when compared to 2003. In addition,
COX-2 selective NSAIDs which accounted for over 40%
of NSAID recommendations in 2003 accounted for only
25% in the current survey. We presume that this
change in utilization was largely driven by increased
concerns regarding the CV safety of these agents
and ⁄ or fear of litigation resulting from recommending
a COX-2 selective NSAID. In fact, over 40% of PCPs felt
that rofecoxib was associated with an increased risk of
MI. However, despite an ever growing body of literature
supporting this association,19, 44 we were surprised to
find that over 40% of PCPs did not feel that rofecoxib
was associated with an increased risk of MI compared
with not using an NSAID. Reflecting the confusion
in the available literature,19, 44 over 50% of PCPs did
not feel that that celecoxib was associated with an
increased risk of MI. This result was similar to the per-
centage of PCPs who were aware of recent literature
suggesting that some traditional NSAIDs may be asso-
ciated with an increased risk of cardiac events.19, 45
Whether the increased risk of adverse CV events
with COX-2 selective NSAIDs and traditional NSAIDs
is drug-specific or represents a class effect remains
controversial. On the basis of meta-analyses, naproxen
appears to be differentiated from other traditional
NSAIDs across the CV risk spectrum.20 Part of the
mechanism of adverse events may be related to block-
ade of aspirin’s access to the platelet COX enzyme ste-
rically by certain NSAIDs, but not COX-2 selective
NSAIDs. This information appeared to be poorly
understood by our survey respondents, as 53% and
33% felt that naproxen and celecoxib respectively
interfered with the antiplatelet effects of aspirin.
One of the main strengths of our study was the
large, geographically diverse group of PCPs who par-
ticipated in the survey. The fact that roughly half of
the questions we asked were the same as in our previ-
ous study and that nearly half of the study cohort also
participated in our previous survey, allowed us to per-
form meaningful comparisons in practice patterns at
two points in time. However, as with any survey, there
were a number of limitations. First, the PCPs were
recruited via e-mail which probably increased the like-
lihood of recruiting younger physicians. For example,
only 1% of our participants in both surveys were
above 65 years old but, according to the American
Medical Association, 18% of physicians are above
65 years old. Because of recently imposed recertifica-
tion standards, which preferentially affect younger
physicians, we speculate that younger physicians are
more likely to be aware of recently published medical
literature. Another limitation is that we do not have
demographic information about PCPs who chose not
to participate in our study. The construct of the survey
did not allow participants to return to a question to
change an answer once completed. We feel that this
limited the influence of questions appearing later in
the survey on answers to questions appearing earlier
in the survey. However, the use of reference materials
when answering survey questions was neither encour-
aged or discouraged in the participant instructions.
That being said, the use of reference materials by par-
ticipants would be expected to have inflated the pro-
portion of ‘correct’ answers to our questions.
In conclusion, our survey identified a number of
areas of improving knowledge regarding PCP knowl-
edge and use of aspirin, traditional NSAIDs, COX-2
selective NSAIDs and GPAs. In addition, our survey
identified a number of areas in need of further educa-
tion regarding the use of these agents. In particular,
ongoing education regarding CV risk calculation when
deciding upon the need for low dose aspirin therapy,
the hazards associated with low dose aspirin therapy
in patients at increased risk for adverse GI outcomes
and a better understanding of GI risk stratification and
the appropriate use of risk reduction strategies in
patients using NSAIDs and COX-2 selective NSAIDs
appears to be warranted.
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